AbbVie bought Allergan and inherited an opioid bill of up to $2.37 billion.

By ··1 min read·2 sources

Allergan had sold its generic opioid business years earlier. The liability stayed, and the settlement carries no admission.

A bipartisan group of attorneys general announced in July 2022 that Allergan would pay up to $2.37 billion to states and local governments over its past opioid sales. The figure includes earlier settlements with individual states. AbbVie, which acquired Allergan in 2020, booked the charge.

Allergan had sold its generics portfolio, opioids included, to Teva in 2016. Teva's own $4.25 billion deal was announced the same week and depended in part on Allergan settling. Together they were worth up to $6.6 billion, more than Johnson & Johnson's nationwide settlement.

Two things follow. A company can sell the business and keep the liability, and an acquirer buys both. And a settlement of this size closed more than 2,500 lawsuits without any finding about the marketing the states alleged.

The check is real. The public record of what Allergan did is no fuller for it.

Sources

  1. doj.state.wi.us · doj.state.wi.us/node/8717
  2. bostonglobe.com · bostonglobe.com/2022/07/29/business/allergan-reaches-tentative-237b-deal-settle-opioid-sui…

Cite this report

The Precedent. "AbbVie bought Allergan and inherited an opioid bill of up to $2.37 billion.." September 20, 2026. https://theprecedent.org/article/abbvie-bought-allergan-and-inherited-an-opioid-bill-of-up-to-237-billion

Companies in this report